Hong Kong’s CK Life To Spin Off U.S. R&D Unit Polynoma, Keep Control
This article was originally published in PharmAsia News
Hong Kong’s CK Life Sciences International intends to establish its U.S.-based subsidiary, Polynoma, as a separate company for research and development, including work on a vaccine for melanoma set to enter Phase III trials.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.